13F Pro quality score
Rank #2,824 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reported revenue, net income and operating margin by fiscal year, from bioAffinity Technologies, Inc.'s annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2025 | 10-K | $6.2M | $-14.9M | -171.6% |
| FY 2024 | 10-K | $9.4M | $-9.0M | -95.6% |
| FY 2023 | 10-K | $7.9M | $-7.9M | -100.9% |
| FY 2022 | 10-K | $6.9M | $-8.2M | -58.1% |
bioAffinity Technologies, Inc. (BIAF) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BIAF at 14.4/100 on a composite quality score built from its SEC filings, placing it at rank #2,824 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), bioAffinity Technologies, Inc. reports quarterly revenue of $1.5M, net income of $-3.4M, free cash flow of $-3.3M. Top institutional holders of BIAF by reported 13-F value include SABBY MANAGEMENT, J. Safra Sarasin Holding AG, BlackRock, based on the most recent SEC filings. BIAF trades on the Nasdaq exchange and files with the SEC under CIK 1712762. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BIAF daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for bioAffinity Technologies, Inc. directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 1712762 →